Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645971 | 0.91 | MAPT (0.47) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5649466 | 0.85 | TACR1 (0.42) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5648096 | 0.84 | MAPT (0.41) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5647087 | 0.81 | MTNR1A (0.40) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL14527172 | 0.80 | HTT (0.62) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5644205 | 0.80 | ADRB3 (0.47) | KDM4EALDH1A1HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL5646572 | 0.79 | MAPT (0.40) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5646577 | 0.79 | MAPT (0.40) | MAPTHTTKDM4EALDH1A1LMNA | |
| SCHEMBL5646889 | 0.79 | HTR2A (0.43) | MAPTMTNR1AMTNR1BTACR1CTSL | |
| SCHEMBL5646191 | 0.79 | MPO (0.49) | MAPTHTTSMN1; SMN2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1421078-B1 | INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | SALL DANIEL J (US) | 2005-07-21 | — | — | US | disclosed |
| US-6911463-B2 | 3-substituted oxindole β-3 agonists | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050080110-A1 | Beta 3 adrenergic agonists | SALL DANIEL JON (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | MAPT 3614/4885HTT 3896/4885KDM4E 3972/4885 |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | MAPT 3541/4885HTT 4035/4885KDM4E 3960/4885 |
| US-20050080110-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | MAPT 3101/4885HTT 4419/4885KDM4E 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.